Efficacy of Chatbot for Irritable Bowel Syndrome (IBS) Patients
Key facts
- Who runs it
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department
- Where
- Moscow, RussiaSee the site
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 54 people, planned
- Started
- Mar 2025
- Planned end
- Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Chatbot supporting system
- Record updated
- 20 February 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults ≥18 years
- Diagnosed with IBS
- Signed informed consent
Who cannot take part
- Patients with other conditions that may influence the endpoints of the current study
- Age under 18 years
- Pregnant individuals
- Patients with cognitive or sensory impairments that hinder understanding of questions in surveys, scales, or instruments used in the study
- Patients unable to use a chatbot
- Patients currently participating in any other clinical trial or experimental study
- Patients with psychotic symptoms
Where in Russia
- Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care DepartmentMoscow, RussiaNo longer taking part
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the efficacy of an automated chatbot system in improving quality of life, reducing depression and anxiety, and decreasing visceral sensitivity in patients with Irritable Bowel Syndrome. The main research question is:
Read full original descriptionShow less
Is an automated chatbot as effective for patients with IBS as standard care? Participants will be asked to complete online surveys to assess quality of life, symptoms of depression and anxiety, and visceral sensitivity before and after the intervention.
The 2 groups in the trial
- Chatbot groupTreatment being tested
The group will receive access to the automated chatbot supporting system. Each patient will receive a unique access code (token) to register for the chatbot. Only patients with tokens present in the authorized database will be able to register, thus ensuring that the chatbot is exclusively used by study participants.
Treatment: Chatbot supporting system
- Standart care groupNo study treatment, for comparison
The group will receive standart care.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of the Efficacy of Chatbot-based Automated Support System for Patients with Irritable Bowel Syndrome (IBS)
- Record updated
- 20 February 2025